血清高尔基体糖蛋白73在肝硬化诊断中的应用及其相关机制

Diagnostic application of serum GP73 and the relevant mechanism in the diagnosis of liver cirrhosis

肝硬化是各种慢性肝脏疾病的终末期改变，早期诊断对患者的治疗及其预后极为重要。尽管肝活组织检查是诊断肝硬化的金标准，但因其有创性，临床应用受限。传统的无创诊断肝硬化指标如天冬氨酸氨基转移酶／血小板比值指数、FIB-4（Fibrosis-4）模型和肝脏弹性指数测定在临床应用上各有其局限性。因此，寻找新的肝硬化血清学指标成为研究热点。根据对既往研究的分析及近期的研究发现，提出了高尔基体糖蛋白73是最有潜力的肝硬化诊断血清标志物的建议。现简要介绍其在肝硬化中的潜在应用价值及其可能的干扰因素，并讨论其相关机制。

Liver cirrhosis is the end-stage change of chronic liver diseases with various causative factors. The accurate diagnosis of liver cirrhosis in an early stage is very important for the timely treatment and prognosis of patients. A liver biopsy test is the gold standard for the diagnosis of liver cirrhosis; but its use is limited in clinical practices due to its invasive nature. The conventional non-invasive measures （APRI, FIB-4 and LSM） for diagnosis of liver cirrhosis could not fulfill the needs. Therefore, finding a new serological marker of liver cirrhosis has become a research hotspot. Based on literature review and our own results, we suggest that serum GP73 as the most potential serum marker for liver cirrhosis diagnosis. This review briefly introduces the application of serum GP73 in the diagnosis of liver cirrhosis and the potential mechanism relevant to its involvement in the development of liver cirrhosis.